Whether AhR activation, via CYP1B1 and CYP1A2, in NK cells and CD8+ T cells, increases the NAS/melatonin ratio and NAS release to activate TrkB on cancer stem-like cells, thereby not only increasing survival and proliferation but also further changing the metabolic interactions in the tumor microenvironment will be important to determine. The gene discussed is NTRK2; the disease is cancer.